Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Boomskidon Jun 22, 2023 3:50pm
115 Views
Post# 35509878

RE:Perhaps the greatest piece of investment wisdom ever...

RE:Perhaps the greatest piece of investment wisdom ever...
You know no such thing, Daniel Carson of Tailwinds Research Group LLC, affectionately known as Tailpipe in our house. I put over $120,000 into stock in 2011 and from 2014 until 2021, I worked about 120 fully documented hours per month as a commentator for and about Bioasis. I wasn't paid for almost 19 months of those years.
 
And for 31 months I was half paid by Bioasis until Mark Day reestablished my pay, with two subsequent raises. In all, I was not paid for $173,000 less than for what I was contracted and completed. Combine that with my investment in Bioasis and I figure I'm out just about $300,000.
 
I gave at the office, Daniel Carlson, and have never deserted the shareholders.
 
You were fired by Bioasis because you brought nothing to the table. Your complaint against me is that I influenced sharedholders. Influencing shareholders was your job, but you were a failure at it. And then you went publicly negative about Bioasis, long before Bioasis deserved such treatment. While you were being paid by Bioasis, you used the sweetest language imaginable in your writings about the company. Next day? Hate.
 
But we understood. You’re a paid tout. You admit it in your disclosures. In fact, your company is actually called DFC Advisory Services LLC, which is doing business as “TW Research Group LLC” which, in turn is different from Tailwinds Research Group. This represents multiple levels of abstraction so that the world doesn’t get too close to Daniel F. Carlson, the “DFC” in DFC Advisory Services LLC, which the thing most carefully guarded, isn’t it, Daniel Carlson. 
 
And are you an investment adviser? Stretching it a bit there, are you, Daniel Carlson, maybe? Can a financial adviser be a tout? Can a tout be a financial adviser? Are you a kangaroo in a man’s suit?
 
And Daniel, I know that you understand your apparent epithet against me because you have made the same statement, yourself, that one should be careful to avoid locking in a loss by selling a swinging stock. It’s a decision faced by all investors throughout their investing lives. The financial media says the same thing during every bearish and bullish market swing. As a “financial adviser" you know that, and so do I.
 
And so do Bioasis shareholders. There are many shareholders who today hope that Bioasis can execute a deal for EGF, or that some other deal may come along in the next few days that will save Bioasis, if only for just a while. There is still a chance. It ain't over until it's over. Personally, I wouldn't bet on it, but there was hope until December 13, 2022 just after the stock hit 20¢ or so. 
 
You do realize, Daniel Carlson, that by trying to ridicule me, you are ridiculing all Bioasis shareholders, and you’re putting DFC Advisory Services LLC, TW Research Group LLC, Tailwinds Research Group and yourself into the Internet, and making all of your public identities look like petty, ignorant, vindictive and incompetent gutter snipes who betray former clients and their shareholders.
 
No, repeat, yes? 
 
jd
<< Previous
Bullboard Posts
Next >>